Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Open Access
- 1 February 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (6), eaav7416
- https://doi.org/10.1126/sciadv.aav7416
Abstract
Secondary drug resistance stems from dynamic clonal evolution during the development of a prior primary resistance. This collateral type of resistance is often a characteristic of cancer recurrence. Yet, mechanisms that drive this collateral resistance and their drug-specific trajectories are still poorly understood. Using resistance selection and small-scale pharmacological screens, we find that cancer cells with primary acquired resistance to the microtubule-stabilizing drug paclitaxel often develop tolerance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), leading to formation of more stable resistant cell populations. We show that paclitaxel-resistant cancer cells follow distinct selection paths under EGFR-TKIs by enriching the stemness program, developing a highly glycolytic adaptive stress response, and rewiring an apoptosis control pathway. Collectively, our work demonstrates the alterations in cellular state stemming from paclitaxel failure that result in collateral resistance to EGFR-TKIs and points to new exploitable vulnerabilities during resistance evolution in the second-line treatment setting.Funding Information
- National Research Foundation of Korea (NRF-2016R1C1B2009886)
- National Research Foundation of Korea (KAISTHEALTHCARE42)
- KAIST (18-C-01)
This publication has 50 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration StrategiesPLoS Computational Biology, 2009
- MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitorsInternational Journal of Cancer, 2009
- The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA ExpressionMolecular and Cellular Biology, 2008
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences of the United States of America, 2005
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002